Get the Stockscreener App
0.7701
4.28%
-0.0344
Bio Path Holdings Inc Stock (BPTH) Latest News
Bio-Path Holdings Expands DNAbilize® Technology Applications - MSN
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research
All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy - Yahoo Finance
Bio-Path stock plunges to 52-week low, hits $0.79 By Investing.com - Investing.com Canada
Bio-Path stock plunges to 52-week low, hits $0.79 - Investing.com
Biotricity, Inc. (NASDAQ:BTCY) Q2 2025 Earnings Call Transcript - Insider Monkey
BIO-key International Reports Financial Results for Third Quarter 2024 - Defense World
First National Corporation (NASDAQ:FXNC) Declares Quarterly Cash Dividend of $0.155 per Share - Defense World
Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD – The Liver Meeting® 2024 - Defense World
Empire Petroleum Corporation Report Q3 2024 Financial and Operating Results - Defense World
Bio-Path Holdings Reports Third Quarter 2024 Financial Results and Expansion into Obesity Program - Defense World
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2024 Earnings Call Transcript - Insider Monkey
Bio-Path: Q3 Earnings Snapshot - New Haven Register
Earnings call: Bio-Path Holdings reports Q3 2024 financials, pipeline updates - Investing.com Canada
Bio-Path Holdings Reports Third Quarter 2024 Financial Results - citybiz
Bio-Path Holdings Expands to Obesity Market, Reports $2.1M Q3 Loss, Raises $4M | BPTH Stock News - StockTitan
Bio-Path Holdings Inc (BPTH) Quarterly 10-Q Report - Quartzy
Some Numbers at Parker Drilling that Make Your Stock Look Good - AOL
Bio Path Holdings Inc expected to post a loss of $1.02 a shareEarnings Preview - XM
Bio-Path (BPTH) Scheduled to Post Quarterly Earnings on Friday - Defense World
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024 - StockTitan
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma - The Manila Times
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
BPTH stock touches 52-week low at $0.84 amid sharp annual decline - Investing.com UK
T-cell Malignancies Clinical Trial Pipeline Insights Featuring 70+ Companies | DelveInsight - The Malaysian Reserve
Antisense Oligonucleotide Therapeutics Market Poised for Significant Growth, Projected to Reach $64.64 Bill... - WhaTech
RNA Interference Therapy Competitive Landscape Report 2024 (Updated) - openPR
Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World
RNA-based Therapeutics Market Latest Trends Analysis Report 2024 - InsightAce Analytic
siRNA Therapeutics Market Set for Explosive Growth, Projected to Reach $48.46 Billion by 2031 - WhaTech
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
siRNA Therapeutics Market Set for Explosive Growth, Expected to Hit $48.46 Billion by 2031 As Revealed In N... - WhaTech
Thyroid Cancer Drug Market to Exhibit a Remarkable CAGR of 17.2% - openPR
Chronic Myeloid Leukemia (CML) Treatment Market Report Analysis, Research Studies |Novartis AG, Bristol-Myers Squibb, Te – IndiaPolitics.com - IndiaPolitics.com
Antisense Oligonucleotide (ASO) Therapeutics Market Size, Share, and Future Growth Analysis (2024-2032) - News in Assen
Antisense and RNAi Therapeutics Market Growth, Share, and Industry Forecast (2024-2032) - News in Assen
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):